Compare Ecolab Inc. (ECL) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Novavax Inc — how do they compare? Ecolab Inc. trades at $281.36 (market cap $77.96B), while Novavax Inc trades at $11.06 (market cap $1.85B). The key difference: Ecolab Inc. is far larger — about 42.1× Novavax Inc's market cap, and Ecolab Inc. pays a 1.05% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 90 Days and Novavax Inc for 59 Days on average.
| ECL | NVAX | |
|---|---|---|
Market Cap | $77.96B | $1.85B |
Volume | 1,145,536 | 8,362,562 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $12.56 |
52-Week Low | $245.73 | $6.22 |
Typical Hold Time | 90 Days | 59 Days |
Enterprise Value | $86.74B | $1.43B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecolab (ECL) trades at $281.69, up 0.31% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $326.38. The company reported revenue of $16.08B in 2025 with a net income margin of 12.57%, and recent earnings have mostly met or exceeded expectations. Strong institutional buying and insider purchases, alongside positive news coverage highlighting its dividend growth and essential business model, support a constructive outlook.
The stock presents a favorable risk-reward profile given its steady revenue growth, high profitability, and analyst optimism, though elevated valuation ratios and increased debt from the CoolIT acquisition pose risks. The upcoming Q3 2026 earnings report on October 27, 2026, will be a key catalyst for near-term price direction.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
